Insider buying last 90 days
No open-market insider purchases were filed for ABT in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Abbott's week centers on Q3 2026 results and a major strategic shift: the company reported sales up 14.5% and adjusted EPS rising 9.2%, though it slightly missed consensus EPS estimates, with adjusted EPS at $1.42 against a $1.42 estimate. Alongside earnings, Abbott outlined plans to spin off its global Nutrition business, which generates approximately $8.5 billion in annual sales, by the end of 2027 to sharpen focus on its medical devices, diagnostics, and medicines segments. Separately, the company's UltiSynq defibrillation lead received FDA approval and a CE mark, expanding its cardiac rhythm management portfolio. Shares also saw some choppiness, falling 1.87% to $107.25 on Thursday and 1.06% to $109.29 on Wednesday, marking a third straight day of losses during that stretch.
Abbott closed at $108.52, up 1.2%, sitting above both its 50-day average of $103.91 and 200-day average of $101.56, with the 50-day above the 200-day. The GekkoIndex reads 53.5, placing it in the Neutral zone. Price remains 12.3% below Gekko Fair Value of $123.74.
Over the next 20 trading days, the next earnings date falls outside that window, set for 28 January 2027. Congressional activity over the past 90 days shows 2 buys and 0 sells, with one billionaire holder noted. Seasonality over 5 years shows the next 20 trading days averaging a 4.3% return, with gains in 3 of those years. Analyst sentiment includes 16 buy ratings against 2 holds and 0 sells among 18 firms, with a consensus target of $118.91.
Written by AI from the Nov 13, 2026 close and checked automatically against the figures on this page.
Abbott Laboratories scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $108.52 is above the 50-day ($103.91) and 200-day ($101.56) averages, and the 50-day is above the 200-day.
See the chart53.5, Neutral
Reading 53.5 is in the Neutral zone.
See the GekkoIndex10.5% below
Price is 10.5% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: Congress 2 buys / 0 sales.
See smart moneyReports in 74 days
Next report Jan 28, 2027, 74 days away — outside a typical 20-trading-day hold.
See earnings+3.9% on average
From this point in the calendar, the next 20 trading days averaged +3.9% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Abbott Laboratories closed at $108.52 on Nov 13, 2026, −15.8% over the past year, inside a 52-week range of $81.97 to $132.03.
Use the left and right arrow keys to read daily values.
Put ABT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Abbott Laboratories works across healthcare, researching, making and distributing a broad range of health products worldwide through its own operations and related entities. It is organized into four areas: established pharmaceuticals, diagnostics, nutrition and medical devices. Its pharmaceutical line includes generic medicines for conditions such as digestive disorders, hormone-related issues, cholesterol and blood pressure management, thyroid problems, vertigo, pain and migraine, along with an anti-infective, flu vaccines and treatments that support colon function.
The diagnostics business supplies laboratory systems for immunoassay, chemistry, hematology and transfusion testing, along with molecular platforms that process DNA and RNA and identify infectious agents. It also makes point-of-care devices, testing cartridges, rapid tests for pathogens including HIV, SARS-CoV-2, influenza and RSV, plus tools for cardiometabolic and substance testing, remote monitoring, consumer self-tests and lab automation software. The nutrition segment produces formulas for infants and adults, while the medical devices unit makes cardiovascular products such as rhythm management and structural heart devices, along with diabetes care tools and neuromodulation devices for pain and movement disorders.
Abbott Laboratories was founded in 1888 and is headquartered in North Chicago, Illinois. Its shares are listed on the NYSE under the ticker ABT.
Abbott Laboratories’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.5, in the Neutral zone, up 4.5 points over five sessions.
Up 4.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | 0.0% | −1.5% | ||
| Accumulation | 268 | +0.1% | +0.6% | ||
| Neutral (current zone) | 371 | +0.1% | −0.2% | ||
| Distribution | 26 | −0.2% | −0.3% | ||
| Selling | 5 | Too few readings yet | |||
Average ABT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Abbott Laboratories trades 10.5% below Gekko Fair Value of $121.31, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Abbott Laboratories shares are worth, recalculated every trading day.
$121.31
Gekko Fair Value, Nov 14, 2026
10.5% Undervalued
At the end of Aug 2026 the price was 12.6% below the estimate.
No open-market insider purchases were filed for Abbott Laboratories, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ABT in the last 90 days.
From Form 4 filings, dated to when each was filed.
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 18 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Abbott Laboratories has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds ABT.
Abbott Laboratories reports on Jan 28, 2027, before the open (74 days away), and beat the EPS estimate in 3 of its last 8 reports.
Jan 28, 2027
Expected before the open, 74 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 21, 2026 | $1.42 est $1.42 | $13.01B est $12.99B | +0.1% |
| Jul 16, 2026 | $1.31 est $1.28 | $12.59B est $12.52B | +12.8% |
| Apr 16, 2026 | $1.15 est $1.15 | — | −4.7% |
| Jan 22, 2026 | $1.50 est $1.49 | $11.46B est $11.80B | −11.0% |
| Oct 15, 2025 | $1.30 est $1.30 | $11.37B est $11.39B | −4.2% |
| Jul 17, 2025 | $1.26 est $1.26 | $11.14B est $11.09B | −6.1% |
| Apr 16, 2025 | $1.09 est $1.07 | $10.36B est $10.41B | +3.8% |
| Jan 22, 2025 | $1.34 est $1.34 | $10.97B est $11.03B | +5.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Abbott Laboratories is $118.91, +9.6% from the last close, from 18 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 18 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 9 | Bank of America Securities | $125 | +15.2% |
| Nov 2 | Piper Sandler | $118 | +8.7% |
| Oct 30 | Bank of America Securities | $115 | +6.0% |
| Oct 27 | Argus Research | — | — |
| Oct 23 | Wells Fargo | $120 | +10.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Abbott Laboratories averaged +3.9% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.4% | 3 of 5 |
| Next 10 trading days | +1.5% | 3 of 5 |
| Next 15 trading days | +1.1% | 3 of 5 |
| Next 20 trading days | +3.9% | 3 of 5 |
| Next 30 trading days | +4.8% | 3 of 5 |
For scale, ABT’s typical 20-trading-day move in either direction is about 4.4%.
Abbott Laboratories’s market cap is $188.0B, with a P/E ratio of 40 and revenue of $48.23B over the last twelve months.
Coverage of Abbott Laboratories this week reads positive: 7 positive, 5 neutral and 5 negative headlines.
Abbott Laboratories’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
| BSXBoston Scientific | Neutral | 25.8% below |
A peer links to its own page where one exists.
Abbott Laboratories’s market cap is $188.0B at the Nov 13, 2026 close of $108.52, with 1.73B shares outstanding. The shares trade on a P/E ratio of 40.
The consensus analyst 12-month price target for Abbott Laboratories is $118.91, +9.6% from the last close. Of the 18 firms that rated the stock in the last 90 days, 16 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Abbott Laboratories is undervalued: the Nov 13, 2026 close of $108.52 is 10.5% below Gekko Fair Value of $121.31. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Abbott Laboratories is expected to report on Jan 28, 2027, before the market opens (74 days away). Analysts expect earnings of $1.64 per share on revenue of $13.21B. Abbott Laboratories beat the earnings estimate in 3 of its last 8 reports, moving 6% on average across the report.
Abbott Laboratories’s 52-week high is $132.03 and its 52-week low is $81.97; it closed at $108.52 on Nov 13, 2026, −15.8% over the past year. Over the last five years the shares peaked at $142.60 on Dec 27, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.